ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: TH-PO164

Changes in Serum Phosphorus Among In-Center Hemodialysis (HD) Patients Initiating Sucroferric Oxyhydroxide (SO) as Part of Routine Care After Kidney Transplant Failure: A 6-Month Follow-Up Study

Session Information

  • CKD-MBD: Targets and Outcomes
    November 03, 2022 | Location: Exhibit Hall, Orange County Convention Center‚ West Building
    Abstract Time: 10:00 AM - 12:00 PM

Category: Bone and Mineral Metabolism

  • 402 Bone and Mineral Metabolism: Clinical

Authors

  • Zhou, Meijiao, Fresenius Medical Care, Waltham, Massachusetts, United States
  • Ficociello, Linda, Fresenius Medical Care, Waltham, Massachusetts, United States
  • Mullon, Claudy, Fresenius Medical Care, Waltham, Massachusetts, United States
  • Anger, Michael S., Fresenius Medical Care, Waltham, Massachusetts, United States
Background

Information on serum phosphorus (sP) management in patients who experience kidney transplant failure (KTF) and initiate dialysis is scarce. This retrospective database analysis aims to assess sP management with sucroferric oxyhydroxide (SO), an iron-based phosphate binder (PB), in post-KTF HD patients (pts) over a 6-month period.

Methods

Eligible pts were adult post-KTF HD pts from Fresenius Kidney Care first prescribed SO monotherapy during 5/2018- 12/2019 who had sP measured in the month before SO start (baseline; BL). Included in the analysis were pts who initiated SO within 12 months from start of post-KTF HD. Comparisons were made between BL and the monthly follow up (FU; M1 through M6). Monthly or quarterly means were calculated using mixed effects linear regression for PB pill burden and lab measurements. A subgroup analysis was performed in pts with post-KTF HD< 3 months.

Results

At BL, pts (n=100) had mean age of 49 years and were on HD for an average of 5 months post-KTF. No PB prescriptions were recorded for 35% overall and 30% for pts with HD <3 months post-transplant. For the overall pts prescribed PB, most were prescribed sevelamer (45%) or calcium acetate (31%). Among pts with HD <3 months post-KTF, fewer patients were on calcium acetate (15%) and more on ferric citrate (19%, compared to 8% overall). After switching to SO, % of pts with sP≤ 5.5 mg/dL increased from 20% to 26%- 35% during SO FU, with fewer PB pills per day in all pts; the trends were similar in pts with post-KTF HD < 3 months (Table). Significant decreases of serum calcium (sCa) and iPTH were also observed.

Conclusion

During a 6-month follow-up, significant reductions in sP, PB pills/day, serum calcium and iPTH were observed after pts switched to sucroferric oxyhydroxide within 1 year of returning to HD after kidney transplant failure.

Funding

  • Commercial Support